Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) has received a consensus recommendation of "Hold" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $6.67.

A number of research analysts recently weighed in on the company. Royal Bank of Canada assumed coverage on Inovio Pharmaceuticals in a research report on Tuesday, July 19th. They set a "sector perform" rating and a $4.00 price objective for the company. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Inovio Pharmaceuticals in a research report on Wednesday, August 17th.

Insider Buying and Selling

In related news, Director David B. Weiner sold 11,875 shares of Inovio Pharmaceuticals stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $2.66, for a total transaction of $31,587.50. Following the transaction, the director now directly owns 892,625 shares in the company, valued at $2,374,382.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Inovio Pharmaceuticals Trading Up 2.7 %

NASDAQ INO opened at $1.73 on Thursday. Inovio Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $7.77. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.18 and a current ratio of 3.18. The stock has a 50 day simple moving average of $2.17 and a two-hundred day simple moving average of $2.36. The stock has a market cap of $430.22 million, a P/E ratio of -1.07 and a beta of 0.82.

Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.18). The firm had revenue of $0.78 million during the quarter, compared to analysts' expectations of $0.52 million. Inovio Pharmaceuticals had a negative net margin of 16,775.78% and a negative return on equity of 94.19%. The company's revenue for the quarter was up 187.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.39) EPS. On average, analysts forecast that Inovio Pharmaceuticals will post -1.39 earnings per share for the current year.

About Inovio Pharmaceuticals

(Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Further Reading

• Get a free copy of the StockNews.com research report on Inovio Pharmaceuticals (INO)
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• Thor Industries Hammers Out A Bottom
• How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.